Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]-Mevidalen disposition study
NCT03616795Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mevidalen in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY3154207 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered at 552 hours and Fecal Excretion of LY3154207 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered at 552 hours. Started Aug 2018; status: completed.
02
Drugs
mevidalen
03
Conditions
dementia with Lewy bodies (DLB)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT03616795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616795.